BG Medicine Inc. (Nasdaq: BGMD) reported that a clinical research study validated the performance of automated VIDAS® Galectin-3 assay. The stock price leaped 24 cents to close at $1.39.
BG Medicine Says VIDAS Galectin-3 Validated
January 28, 2014 at 10:43 AM EST
